New global analysis confirms alcohol’s complex relationship with health: clear cancer risks and chronic liver diseases at any level, mixed evidence for other cardiometabolic conditions
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 03:16 ET (22-Jun-2026 07:16 GMT/UTC)
The largest real-world study ever conducted on prostate cancer in Brazil analyzed data from 670,205 patients treated through the Brazilian Unified Health System (SUS) over a 16-year period, between 2008 and 2023. Published in the Journal of Global Oncology (JCO), the official journal of the American Society of Clinical Oncology (ASCO), the study included researchers from the D’Or Institute for Research and Education (IDOR) and investigated patterns of diagnosis, treatment, and healthcare costs related to the disease across the country. The results revealed significant racial inequalities, including a higher frequency of advanced disease at diagnosis among non-white men and differences in therapeutic investment.
Nine out of 10 prescriptions are filled by generic drugs — FDA-approved carbon copies of brand-name drugs with expired patents. Over the last 30 years, generic drugs have saved trillions of dollars for hundreds of millions of people. But newer biologic medicines, including blockbuster treatments for diabetes, cancer, and autoimmune disease, are harder to manufacture into generic form. Unlike traditional “small molecule” drugs made from chemicals, biologics are large, protein-sized molecules made in living cells. Their equivalents, called biosimilars, are close but not identical copies. Now, a study from UC San Francisco researchers shows that the regulations for biosimilars vary around the world, slowing their development and adoption.
A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) in Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors. The results show overall good tolerability and clear signs of effectiveness of this novel immunotherapy. They are published in the renowned scientific journal Nature Medicine.